All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) shot 237% higher to $18 Nov. 11 on new top-line results for its targeted antibody, bemarituzumab, in gastric cancer.
